Industry publications generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy and completeness of the information. We obtained the statistical data, market data and other industry data and forecasts described in this prospectus from market research, publicly available information and industry publications. Persons outside the United States who come into possession of this prospectus must inform themselves about and observe any restrictions relating to the offering of the ordinary shares and the distribution of the prospectus outside the United States. We have not taken any action to permit a public offering of the ordinary shares outside the United States or to permit the possession or distribution of this prospectus outside the United States. The information contained in this prospectus is current only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the ordinary shares. We are offering to sell, and seeking offers to buy, the ordinary shares only in jurisdictions where offers and sales are permitted. We have not authorized anyone to provide you with information different from that contained in this prospectus or any free-writing prospectus. You should rely only on the information contained in this prospectus and in any related free-writing prospectus. Where You Can Find Additional Information Management’s Discussion and Analysis of Financial Condition and Results of OperationsĬertain Relationships and Related Party Transactions The date of this prospectus is April 6, 2021.Ĭautionary Note Regarding Forward-Looking Statements The underwriters expect to deliver the ordinary shares to purchasers in the offering on or about April 8, 2021.īrilliant Norton Securities Company Limited See “Underwriting” for additional information. We have also agreed to reimburse the underwriters for certain expenses incurred by them.
(1) Boustead Securities, LLC, the representative of the underwriters (the “Representative”), will receive compensation, in addition to the underwriting discounts and commissions, as set forth in the section entitled “Underwriting,” upon the closing of this offering. Underwriting discounts and commissions(1) Any representation to the contrary is a criminal offense. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. See “Risk Factors” beginning on page 15 of this prospectus for a discussion of information that should be considered before making a decision to purchase our ordinary shares.
Investing in our ordinary shares is highly speculative and involves a significant degree of risk. We are an “emerging growth company”, as that term is used in the Jumpstart Our Business Startups Act of 2012, and will be subject to reduced public company reporting requirements. However, the closing of this offering is contingent upon the successful listing of our ordinary shares on the Nasdaq Capital Market. Our ordinary shares have been approved for listing on the Nasdaq Capital Market, or NASDAQ, under the symbol “ UTME.” We cannot guarantee that we will be successful in listing our ordinary shares on the Nasdaq Capital Market. No public market currently exists for our ordinary shares. The initial public offering price is $4.00 per share. Prior to this offering, there has been no public market for our ordinary shares. We are offering 3,750,000 of our ordinary shares in a firm commitment underwritten public offering. This is the initial public offering of ordinary shares of UTime Limited, a Cayman Islands exempted company.
0 kommentar(er)
